Results 11 to 20 of about 161,851 (302)

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

Human Vaccines & Immunotherapeutics, 2021
Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older adults.
Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha A. Railkar, Xin Cao, Wen Liu, Jeffrey R. Sachs, Christine J. Swenson, Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther   +17 more
doaj   +2 more sources

Why has the epidemiology of RSV changed during the COVID-19 pandemic?

EClinicalMedicine, 2023
Summary The coronavirus disease 2019 (COVID-19) pandemic has drastically perturbed the epidemiology of Respiratory Syncytial Virus (RSV) respiratory tract infections in children. The reasons for this are not clear.
B. Abu-Raya, M. Viñeta Paramo, F. Reicherz, P. Lavoie   +3 more
semanticscholar   +1 more source

Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling Study

Infectious Disease and Therapy, 2023
Introduction Previous studies suggest diagnostic testing characteristics (i.e. variations in clinical specimens and diagnostic tests) can contribute to underestimation of RSV disease burden.
You Li, D. Kulkarni, Elizabeth Begier, P. Wahi-Singh, B. Wahi-Singh, B. Gessner, H. Nair   +6 more
semanticscholar   +1 more source

Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis

Open Forum Infectious Diseases, 2022
Background Adult respiratory syncytial virus (RSV) vaccines are in the late stages of development. A comprehensive synthesis of adult RSV burden is needed to inform public health decision-making. Methods We performed a systematic review and meta-analysis
J. McLaughlin, F. Khan, Elizabeth Begier, D. Swerdlow, L. Jodar, A. Falsey   +5 more
semanticscholar   +1 more source

Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology and clinical course compared to influenza A / B and the original SARS-CoV-2 strain

Journal of Clinical Virology, 2023
Background The role and impact of RSV in the adult population is not well understood and comparative data of RSV infection, influenza A/B and SARS-CoV-2 in the elderly hospitalized for respiratory infections is limited.
A. Ambrosch, Doris Luber, F. Klawonn, M. Kabesch   +3 more
semanticscholar   +1 more source

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

Pathogens, 2023
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease, especially in young children. Despite its global impact on healthcare, related to its high prevalence and its association with significant morbidity, the ...
D. Gatt, I. Martin, R. Alfouzan, T. Moraes   +3 more
semanticscholar   +1 more source

Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States

Infectious Disease and Therapy, 2023
Introduction Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI)-related hospitalizations in older adults. Without RSV-specific treatment for adults, testing is uncommon, leading to potential underestimation ...
M. Rozenbaum, Jennifer Judy, D. Tran, K. Yacisin, S. Kurosky, Elizabeth Begier   +5 more
semanticscholar   +1 more source

Off-season RSV epidemics in Australia after easing of COVID-19 restrictions

Nature Communications, 2021
Human respiratory syncytial virus (RSV) is an important cause of acute respiratory infection with the most severe disease in the young and elderly.
John-Sebastian Eden, C. Sikazwe, Ruopeng Xie, Yi-Mo Deng, Sheena G. Sullivan, Alice Michie, A. Levy, Elena J Cutmore, C. Blyth, P. Britton, N. Crawford, Xiaomin Dong, D. Dwyer, Kimberly M. Edwards, B. Horsburgh, D. Foley, K. Kennedy, C. Minney-Smith, D. Speers, R. Tulloch, E. Holmes, V. Dhanasekaran, David W Smith, J. Kok, I. Barr   +24 more
semanticscholar   +1 more source

Neonatal priming and infancy boosting with a novel respiratory syncytial virus vaccine induces protective immune responses without concomitant respiratory disease upon RSV challenge

Human Vaccines & Immunotherapeutics, 2020
Although respiratory syncytial virus (RSV) infection in infants and young children is a global public health issue, development of a safe RSV vaccine has been impeded by formalin-inactivated RSV-enhanced respiratory disease (ERD).
Shuren Zhang, Gan Zhao, Caixia Su, Chaofan Li, Xian Zhou, Weidong Zhao, Yiwei Zhong, Zhonghuai He, Haichang Peng, Aihua Dong, Bin Wang   +10 more
doaj   +1 more source

Maternal RSV vaccine development. Where to from here?

Human Vaccines & Immunotherapeutics, 2021
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection and is responsible for a large proportion of infant morbidity and mortality worldwide.
Ahinsa Gunatilaka, Michelle L. Giles
doaj   +1 more source